Skip to main content
Erschienen in:

02.08.2017 | short review

ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?

verfasst von: Joanna Szkandera, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Summary

Soft tissue sarcomas (STS) are a rare and heterogeneous group of malignant tumors that substantially differ in the underlying biology, natural course and treatment response. In locally advanced or metastatic disease, systemic treatment represents the main therapeutic approach. Anthracycline-based chemotherapy and its combination with ifosfamide has been used as the gold standard in the first-line treatment of advanced disease for decades; however, as increasing evidence favors the use of histology-tailored therapy, novel cytotoxic agents and targeted therapies are currently under intense investigation. Additionally, immunotherapeutic agents have been explored in several STS studies, showing promising results in specific histological subtypes. This article provides a brief overview of the standard systemic treatment options in advanced STS and a summary of the highlights of the STS trials presented at the American Society of Clinical Oncology (ASCO) annual meeting 2017.
Literatur
1.
Zurück zum Zitat Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and Bone, 4th ed. WHO classification of tumours. vol 5. Lyon: IARC Press; 2013. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and Bone, 4th ed. WHO classification of tumours. vol 5. Lyon: IARC Press; 2013.
3.
4.
Zurück zum Zitat Blum RH, Edmonson J, Ryan L, Pelletier L. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 1993;31(Suppl 2):238–40. Blum RH, Edmonson J, Ryan L, Pelletier L. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol. 1993;31(Suppl 2):238–40.
5.
Zurück zum Zitat Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of Trabectedin or Dacarbazine for metastatic Liposarcoma or Leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized Multicenter clinical trial. J Clin Oncol. 2016;34(8):786–93. doi:10.1200/JCO.2015.62.4734.CrossRefPubMed Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of Trabectedin or Dacarbazine for metastatic Liposarcoma or Leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized Multicenter clinical trial. J Clin Oncol. 2016;34(8):786–93. doi:10.​1200/​JCO.​2015.​62.​4734.CrossRefPubMed
6.
Zurück zum Zitat van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. doi:10.1016/S0140-6736(12)60651-5.CrossRefPubMed van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. doi:10.​1016/​S0140-6736(12)60651-5.CrossRefPubMed
7.
Zurück zum Zitat Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–37. doi:10.1016/S0140-6736(15)01283-0.CrossRefPubMed Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–37. doi:10.​1016/​S0140-6736(15)01283-0.CrossRefPubMed
9.
Zurück zum Zitat Chawla SP, Ganjoo KN, Schuetze S, Papai Z, Van Tine BA, Choy E, et al. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. J Clin Oncol. 2017;35(suppl), abstr. 11000. Chawla SP, Ganjoo KN, Schuetze S, Papai Z, Van Tine BA, Choy E, et al. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. J Clin Oncol. 2017;35(suppl), abstr. 11000.
11.
Zurück zum Zitat Tawbi HAH, Burgess M, Crowley J, Van Tine B, Hu J, Schuetze S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028–A multicenter phase II study. J Clin Oncol. 2016;34(suppl):abstr 11006. Tawbi HAH, Burgess M, Crowley J, Van Tine B, Hu J, Schuetze S, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028–A multicenter phase II study. J Clin Oncol. 2016;34(suppl):abstr 11006.
12.
Zurück zum Zitat Burgess MA, Bolejack V, Van Tine BA, Schuetze S, Hu J, D’Angelo SP, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35(suppl):abstr. 11008. Burgess MA, Bolejack V, Van Tine BA, Schuetze S, Hu J, D’Angelo SP, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35(suppl):abstr. 11008.
13.
Zurück zum Zitat D’Angelo SP, Mahoney MR, Van Tine BA, Atkins JN, Milhem MM, Tap WD, et al. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol. 2017;35(suppl):abstr. 11007. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins JN, Milhem MM, Tap WD, et al. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol. 2017;35(suppl):abstr. 11007.
15.
Zurück zum Zitat Broto JM, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, Casali PG. Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. J Clin Oncol. 2017;35(suppl):abstr. 11003. Broto JM, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, Casali PG. Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. J Clin Oncol. 2017;35(suppl):abstr. 11003.
16.
18.
Zurück zum Zitat Judson IR, Morden JP, Leahy MG, Bhadri V, Campbell-Hewson Q, Cubedo R, et al. Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CAPSP (cediranib in ASPS), an international, randomized phase II trial (C2130/A12118). J Clin Oncol. 2017;35(suppl):abstr. 11004. Judson IR, Morden JP, Leahy MG, Bhadri V, Campbell-Hewson Q, Cubedo R, et al. Activity of cediranib in alveolar soft part sarcoma (ASPS) confirmed by CAPSP (cediranib in ASPS), an international, randomized phase II trial (C2130/A12118). J Clin Oncol. 2017;35(suppl):abstr. 11004.
Metadaten
Titel
ASCO update – what is new in the systemic treatment of advanced soft tissue sarcomas?
verfasst von
Joanna Szkandera, MD
Publikationsdatum
02.08.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0346-0

Weitere Artikel der Ausgabe 4/2017

memo - Magazine of European Medical Oncology 4/2017 Zur Ausgabe